Gilead ups its bet on HIV, hep B, ink­ing $400M part­ner­ship with im­munother­a­py com­pa­ny Hookipa

In search of new as­sets to bol­ster its lead­ing HIV fran­chise, Gilead is en­list­ing the help of im­munother­a­py spe­cial­ists at Hookipa Biotech to bring in some fresh R&D.

Topped with $10 mil­lion up­front and worth up to $400 mil­lion, the deal gives Gilead ex­clu­sive ac­cess to Hookipa’s are­navirus vec­tor-based im­mu­niza­tion tech­nolo­gies, Vaxwave and Ther­aT. As well as HIV, the Fos­ter City, CA-based big biotech will al­so take a crack at he­pati­tis B us­ing these vi­ral plat­forms.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.